Aptose Biosciences Inc. Annual report [Section 13 and 15(d), not S-K Item 405]

Annual report [Section 13 and 15(d), not S-K Item 405]

Cover
- Document And Entity Information
Financial Statements
Notes to Financial Statements
Accounting Policies
- Note 2 - Significant Accounting Policies (Policies)
Notes Tables
Notes Details

Note 15 - Stock-based Compensation (Tables)

v3.26.1

Note 15 - Stock-based Compensation (Tables)

12 Months Ended

Dec. 31, 2025

Notes To Financial Statements [Abstract]

Share-based Payment Arrangement, Option, Activity

Stock option activity for the year ended December 31, 2025 is as follows:




	Options			Weighted average exercise price		Weighted average remaining contractual life (years)		Aggregate intrinsic value

Outstanding, December 31, 2024		39,489		$	1,170.30
Granted		—			—
Forfeited		(2,119	)		1,493.05
Outstanding, December 31, 2025		37,370		$	1,159.30		5.6	$	—
Exercisable, December 31, 2025		29,774		$	1,398.48		5.1	$	—
Vested and expected to vest, December 31, 2025		35,499		$	1,209.37		5.5	$	—

Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions

The following table presents the weighted average assumptions that were used in the Black‑Scholes option pricing model to determine the fair value of stock options granted during the prior period, and the resultant weighted average fair values:


	Year ended December 31, 2024
Risk-free interest rate		4.07	%
Expected dividend yield		—
Expected volatility		83.1	%
Expected life of options (years)		5
Grant date fair value	$	40.80

Schedule of Share-based Payment Award, Options, Grants in Period

The following table presents the vesting terms of options granted in the prior period:


	Year ended December 31, 2024

	Options
3-year vesting (50%-25%-25%)		667
4-year vesting (50%-16 2/3%-16 2/3%-16 2/3%)		12,939
Total stock options granted in the year		13,606

Share-based Payment Arrangement, Expensed and Capitalized, Amount

The Company recorded share-based compensation expense related to stock options as follows:


	Year ended December 31, 2025		Year ended December 31, 2024
Research and development	$	182	$	346
General and administrative		295		714
Total	$	477	$	1,060

- Definition

Notes To Financial Statements Abstract

+ References

No definition available.

+ Details

Name:	none_NotesToFinancialStatementsAbstract
Namespace Prefix:	none_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Tabular disclosure of share options granted during the period.

+ References

No definition available.

+ Details

Name:	none_ScheduleOfSharebasedPaymentAwardOptionsGrantsInPeriodTableTextBlock
Namespace Prefix:	none_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

- Definition

Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (h)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

+ Details

Name:	us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

- Definition

Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (d)
-SubTopic 10
-Topic 718
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (e)
-SubTopic 10
-Topic 718
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

+ Details

Name:	us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

- Definition

Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 718
-SubTopic 10
-Subparagraph (f)(2)
-Name Accounting Standards Codification
-Paragraph 2
-Section 50
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

+ Details

Name:	us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration